This Article Full Text Full Text (PDF) All Versions of this Article: 91/12/4817    most recent Author Manuscript (PDF) Submit a related Letter to the Editor View responses Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stan, M. N. Articles by Bahn, R. S. Search for Related Content PubMed PubMed Citation Articles by Stan, M. N. Articles by Bahn, R. S. Related Collections Thyroid Autoimmunity

Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Release Octreotide for Treatment of Graves’ Ophthalmopathy

Department of Internal Medicine (M.N.S., M.D.B., R.S.B.), Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Ophthalmology (J.A.G., E.A.B., J.J.W.), Department of Radiology (M.M.B.), Division of Neuroradiology, and Department of Health Sciences Research (S.C.B., S.J.A.), Division of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Rebecca S Bahn, M.D., Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. E-mail: bahn.rebecca{at}mayo.edu.

Context: Despite a strong rationale for trials of somatostatin analogs in the treatment of Graves’ ophthalmopathy (GO), recent studies have provided conflicting results.

Objective: The objective of the study was to determine whether octreotide long-acting release (LAR) is effective treatment for active GO.

Design: This was a prospective, randomized, double-blind, placebo-controlled study.

Setting: The setting was a single tertiary referral center.

Patients: Twenty-nine consecutive euthyroid patients with active GO [clinical activity score (CAS) 3] were enrolled; 25 completed the study.

Intervention: Patients received four monthly doses of either octreotide LAR (20 mg) or saline by im injections.

Main Outcome Measures: Primary measure was a change in CAS; the secondary measure was changes in retrobulbar tissue volume, proptosis, lid fissure width, range of motion, and diplopia fields.

Results: Median (range) CAS change was 2.5 (1, 5) in the treatment and 1.0 (0, 7) in the placebo group (P = 0.02). Median lid fissure width improved in the treatment group, (decreased 1 mm on the right and 0.5 mm on the left), compared with the placebo group (no change on the right, P < 0.01; increased 1 mm on the left, P < 0.01). No other significant differences between groups were identified.

Conclusions: CAS improved to a greater extent in octreotide-LAR-treated patients than the control group. However, this finding may not represent clinical benefit because patients with higher baseline CAS were overrepresented in the treatment group, and the control group was small. In contrast, treatment-related improvement in eyelid fissure width was noted, suggesting that octreotide LAR may be useful in the treatment of a subgroup of active GO patients with significant lid retraction.

This article has been cited by other articles:

				L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF]

				I. Cozma, L. Zhang, J. Uddin, C. Lane, A. Rees, and M. Ludgate Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1630 - E1635. [Abstract] [Full Text] [PDF]

eLetters: